This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Sat, March 21, 2026 astatine 5:33 PM CDT 4 min read

Kynam Capital Management trimmed its involvement successful Viridian Therapeutics (NASDAQ:VRDN), selling 2,957,386 shares successful the 4th quarter, an estimated $81.11 cardinal transaction based connected quarterly mean pricing, according to a February 17, 2026, SEC filing.

According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management reduced its holding successful Viridian Therapeutics by 2,957,386 shares during the 4th quarter. The estimated transaction worth is $81.11 million, calculated utilizing the mean closing terms for the quarter. The worth of the Viridian involvement astatine quarter-end declined by $49.79 million, a fig that includes some trading and marketplace terms effects.

The money sold shares, bringing its Viridian involvement to 2.92% of 13F reportable assets nether management.
Top 5 holdings aft the filing:
- NASDAQ:COGT: $218.99 cardinal (14.3% of AUM)
- NASDAQ:VERA: $173.85 cardinal (11.3% of AUM)
- NASDAQ:SNDX: $169.15 cardinal (11.0% of AUM)
- NASDAQ:CLDX: $161.42 cardinal (10.5% of AUM)
- NASDAQ:PCVX: $134.84 cardinal (8.8% of AUM)
As of Friday, Viridian shares were priced astatine $26.98, up 76% implicit the past twelvemonth and good outperforming the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$26.98
Market capitalization	$2.8 billion
Revenue (TTM)	$70.79 million
Net income (TTM)	($342.6 million)

Viridian Therapeutics develops monoclonal antibody therapies, with a existent absorption connected treatments for thyroid oculus illness (TED), including pb candidates VRDN-001, VRDN-002, and VRDN-003.
The company’s concern exemplary is centered connected probe and improvement of caller biologics, advancing candidates done objective trials to execute regulatory support and aboriginal commercialization.
Viridian chiefly targets healthcare providers and patients affected by superior diseases, with an accent connected the biotechnology market.

Viridian Therapeutics, Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of innovative antibody-based therapies for superior diseases. With a pipeline led by candidates targeting thyroid oculus disease, the institution leverages precocious monoclonal antibody exertion to code unmet aesculapian needs. Viridian’s strategy is rooted successful technological expertise and a absorption connected high-value specialty markets, positioning it to vie successful the evolving biotechnology sector.

When a biotech presumption balloons this quickly, trimming becomes little astir condemnation and much astir control. Viridian had turned into 1 of the fund’s halfway bets, with astir $100 cardinal worthy of holdings. But aft a staggering banal tally implicit the past year, this trim seems similar an effort to right-size hazard without walking distant from the communicative entirely.

Viridian heads into a pivotal agelong with a June 30 PDUFA day for veligrotug, positive aggregate Phase 3 readouts for its follow-on campaigner VRDN-003 expected this year. At the aforesaid time, it is spending heavy to get there, with probe and improvement costs climbing to astir $339 cardinal and a full-year nett nonaccomplishment of astir $343 million. That said, the equilibrium expanse helps offset that risk, with astir $875 cardinal successful currency astatine year-end. For semipermanent investors, this remains a high-conviction pipeline story, but 1 present sized much appropriately aft a large run. Upcoming information volition play a pivotal relation successful however the show holds up.

Read Entire Article